IONIS PHARMACEUTICALS

Company snapshot

IONIS PHARMACEUTICALS maintains 128 tracked programs across Hypertriglyceridemia, Type 2 Diabetes Mellitus, Familial Chylomicronemia Syndrome, Hereditary Transthyretin-Mediated Amyloid Polyneuropathy, Hereditary Angioedema, Elevated Lipoprotein(a), Hypercholesterolemia, Type 2 Diabetes, Angelman syndrome, Multiple System Atrophy, Alexander Disease, Hereditary Angioedema (HAE). Momentum score: 24/1

• 2 approved product(s) across US/EU regulatory metadata.
• 128 active pipeline program(s) linked via ClinicalTrials.gov.
• 222 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for IONIS PHARMACEUTICALS. Not investment advice.

• Peer + 0 momentum

  Takeda

  TA overlap score 50

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 40

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  Sanofi Pasteur MSD

  TA overlap score 36.6

• Peer + 0 momentum

  Biocryst

  TA overlap score 27.4

Recent activity

Latest pipeline, patent, and corporate events for IONIS PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   ION373-CS1 — Phase 2

2. Jun 8, 2026 Clinical update

   ISIS 678354-CS5 — Phase 3

3. Jun 8, 2026 Clinical update

   ISIS 678354-CS13 — Phase 3

4. Jun 8, 2026 Clinical update

   ION363-CS1 — Phase 3

5. Jun 8, 2026 Clinical update

   ION269-CS1 — Phase 1

View all clinical trial activity →

• What is IONIS PHARMACEUTICALS?

  IONIS PHARMACEUTICALS is a pharma organization headquartered in Carlsbad, USA. It trades on NYSE under ticker IONS. Primary therapeutic focus areas include Hypertriglyceridemia, Type 2 Diabetes Mellitus, Familial Chylomicronemia Syndrome, Hereditary Transthyretin-Mediated Amyloid

• Is IONIS PHARMACEUTICALS publicly traded?

  Yes. IONIS PHARMACEUTICALS is listed with ticker IONS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does IONIS PHARMACEUTICALS develop or market?

  We link 48 drug profile(s) where IONIS PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ionis-pharmaceuticals-inc#company-drugs.

• What are the latest developments for IONIS PHARMACEUTICALS?

  In the last 12 months our linked public records show 128 trial program update(s) and 8 US patent grant(s) tied to this profile.

• What therapeutic areas does IONIS PHARMACEUTICALS focus on?

  IONIS PHARMACEUTICALS focuses on Hypertriglyceridemia, Type 2 Diabetes Mellitus, Familial Chylomicronemia Syndrome based on our analysis of their pipeline programs and drug development activities.